The Risk of Sympathetic Ophthalmia after Vitreoretinal Surgery.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
05 2022
Historique:
received: 11 10 2021
revised: 12 01 2022
accepted: 18 01 2022
pubmed: 31 1 2022
medline: 11 5 2022
entrez: 30 1 2022
Statut: ppublish

Résumé

To investigate the clinical course and outcomes of sympathetic ophthalmia (SO) and correlate these with the nature of the inciting event and the number of vitreoretinal (VR) procedures undergone by patients. A retrospective case review. All patients diagnosed with SO who had been treated or monitored at a single center over a 15-year period. A search of the electronic patient record system at Moorfields Eye Hospital, London, over a 15-year period (between January 2000 and December 2015) was carried out using the search terms "sympathetic," "ophthalmia," and "ophthalmitis." Sixty-one patients with available records were identified, and data were collected from their complete electronic and paper records. The main outcome measures were best-corrected visual acuity at 1 year and at the end of follow-up and the number of VR surgical procedures preceding the diagnosis of SO. Data on patient age, sex, disease duration, ocular and systemic manifestations, ocular complications, retinal angiography, and treatment were also collected. There was a wide age range at presentation (2-84 years), and the length of follow-up ranged from 1 to 75 years. The first ocular event was trauma in 40 patients and surgery in 21 patients. Vitreoretinal surgery accounted for 13 of the 21 (62%) surgical first-event triggers. Twenty-three of 61 (38%) patients underwent VR surgery (1-7 operations) at some point before diagnosis. Surgical details were available for 15 patients, who had undergone a total of 25 VR procedures. Based on the surgical activity of the unit, the risk of developing SO after a single VR procedure was estimated to be 0.008%, rising to 6.67% with 7 procedures. A total of 23 (38%) patients experienced a decrease in acuity at the end of the follow-up period, vs. 9 (15%) patients experiencing an improvement and 18 (30%) remaining unchanged. We feel that the most significant finding in this study is the calculated risk of SO development after a single VR procedure, which was significantly lower in our cohort than that previously reported in the literature. This was seen to rise exponentially with additional procedures.

Identifiants

pubmed: 35093583
pii: S2468-6530(22)00034-3
doi: 10.1016/j.oret.2022.01.012
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

347-360

Subventions

Organisme : Medical Research Council
ID : MR/T000953/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Evgenia Anikina (E)

Vitreoretinal Service, Moorfields Eye Hospital NHSFT, London, United Kingdom; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHSFT, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom.

Siegfried K Wagner (SK)

Vitreoretinal Service, Moorfields Eye Hospital NHSFT, London, United Kingdom; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHSFT, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom.

Sidath Liyanage (S)

Vitreoretinal Service, Moorfields Eye Hospital NHSFT, London, United Kingdom; NIHR Biomedical Research Centre at Moorfields Eye Hospital NHSFT, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom.

Paul Sullivan (P)

Vitreoretinal Service, Moorfields Eye Hospital NHSFT, London, United Kingdom.

Carlos Pavesio (C)

NIHR Biomedical Research Centre at Moorfields Eye Hospital NHSFT, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom; Uveitis Service, Moorfields Eye Hospital NHSFT, London, United Kingdom.

Narciss Okhravi (N)

NIHR Biomedical Research Centre at Moorfields Eye Hospital NHSFT, London, United Kingdom; UCL Institute of Ophthalmology, London, United Kingdom; Uveitis Service, Moorfields Eye Hospital NHSFT, London, United Kingdom. Electronic address: narciss.okhravi@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH